Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 5/2014

01-10-2014 | Review

Recommendations for the management of acute hepatitis B: position paper of the Italian Society for the Study of Infectious and Tropical Diseases (SIMIT)

Authors: R. Bruno, G. Carosi, N. Coppola, G. B. Gaeta, M. Puoti, T. Santantonio, G. Taliani, O. Armignacco, E. Sagnelli, M. Andreoni, G. Angarano, G. Di Perri, G. D’Offizi, M. Galli, G. Rizzardini

Published in: Infection | Issue 5/2014

Login to get access

Abstract

Purpose

To develop recommendations for the management of acute hepatitis B by the Italian Society for the Study of Infectious and Tropical Diseases.

Methods

Development of the recommendations divided into three levels of evidence according to the GRADE system: A (high), B (medium) and C (low experts opinion), together with three recommendation levels: 1 (strong), 2 (medium), 3 (weak).

Results

The treatment with antivirals is in selected cases the mainstay of management of severe acute hepatitis, and should be started as a matter of urgency in order to prevent death.

Conclusions

These recommendations are meant to provide the rationale and practical indications for the management of acute hepatitis B (AHB).
Literature
1.
Kumar M, Satapathy S, Monga R, et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology. 2007;45:96–101.CrossRef
2.
Yu JW, Sun LJ, Zhao YH, et al. The study of efficacy of lamivudine in patients with severe acute hepatitis B. Dig Dis Sci. 2010;56:775–83.CrossRef
3.
Tillmann HL, Hadem J, Leifeld L, Zachou K, Canby A, Eisenbach C, et al. Safety and efficacy of lamivudine in patients with severe acute fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006;13:256–63.
4.
European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85.
5.
Ito K, Yotsuyanagi H, Yatsuhashi H, Karino Y, Takikawa Y, Saito T, Arase Y, Imazeki F, Kurosaki M, Umemura T, Ichida T, Toyoda H, Yoneda M, Mita E, Yamamoto K, Michitaka K, Maeshiro T, Tanuma J, Tanaka Y, Sugiyama M, Murata K, Masaki N, Mizokami M; Japanese AHB Study Group. Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults. Hepatology. 2014;59(1):89–97. doi:10.​1002/​hep.​26635.
6.
Chulanov VP, Shipulin GA, Schaefer S, Gerlich WH. Kinetics of HBV DNA and HBsAg in acute hepatitis B patients with and without coinfection by other hepatitis viruses. J Med Virol. 2003;69:313–23.PubMedCrossRef
7.
Baxa DM, Thekdi AD, Golembieski A, Krishnan PV, Sharif O, Kizy A, Shetron-Rama L, Jovanovich J, Chappell BJ, Snow-Lampart A, Borroto-Esoda K, Gordon SC. Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United States. J Hepatol. 2013;58:212–6.PubMedCrossRef
8.
Coppola N, Tonziello G, Colombatto P, Pisaturo M, Messina V, Moriconi F, Alessio L, Sagnelli C, Cavallone D, Brunetto M, Sagnelli E. Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B. J Infect. 2013;67:322–8.PubMedCrossRef
9.
European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227–42.CrossRef
10.
Tillmann HL, Zachou K, Dalekos GN. Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat? Liver Int. 2012;32:544–53.PubMedCrossRef
11.
Rapicetta M, Ferrari C, Levrero M. Viral determinants and host immune responses in the pathogenesis of HBV infection. J Med Virol. 2002;67:454–7.PubMedCrossRef
12.
Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improve the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology. 2011;53:774–80.PubMedCrossRef
13.
Galli M, Crocchiolo P, Negri C, et al. Attempt to treat acute type B hepatitis with an orally administered thymic extract (thymomodulin): preliminary results. Drugs Exp Clin Res. 1985;11:665–9.PubMed
14.
Galský J, Bansky G, Holubová T, Kõnig J. Effect of ursodeoxycholic acid in acute viral hepatitis. J Clin Gastroenterol 1999;28:249–53.
15.
Fabris P, Tositti G, Mazzella G, Zanetti AR, Nicolin R, Pellizzer G, Benedetti P, de Lalla F. Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study. Aliment Pharmacol Ther. 1999;13:1187–93.
16.
Weiss L, Hildt E, Hofschneider PH. Anti-hepatitis B virus activity of N-acetyl-l-cysteine (NAC): new aspects of a well-established drug. Antivir Res. 1996;32:43–53.PubMedCrossRef
17.
Gunduz H, Karabay O, Tamer A, et al. N-acetyl cysteine therapy in acute viral hepatitis. World J Gastroenterol. 2003;9:2698–700.PubMed
18.
Evans TW. Review article: albumin as a drug—biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther. 2002;16:6–11.PubMedCrossRef
19.
Laleman W, Wilmer A, Evenepoel P, et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2006;10(4):R108.
20.
Schmidt LE, Wang LP, Hansen BA, et al. Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: a prospective controlled trial. Liver Transpl. 2003;9:290–7.PubMedCrossRef
21.
Saliba F, Camus C, Durand F, et al. Randomized controlled multicentre trial evaluating the efficacy and safety of albumin dialysis with MARS in patients with fulminant and subfulminant hepatic failure. Hepatology 2008;48:LB1.
Metadata
Title
Recommendations for the management of acute hepatitis B: position paper of the Italian Society for the Study of Infectious and Tropical Diseases (SIMIT)
Authors
R. Bruno
G. Carosi
N. Coppola
G. B. Gaeta
M. Puoti
T. Santantonio
G. Taliani
O. Armignacco
E. Sagnelli
M. Andreoni
G. Angarano
G. Di Perri
G. D’Offizi
M. Galli
G. Rizzardini
Publication date
01-10-2014
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 5/2014
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-014-0642-0

Other articles of this Issue 5/2014

Infection 5/2014 Go to the issue

Original Paper

Minimum spread of the new Swedish variant of Chlamydia trachomatis and distribution of C. trachomatis ompA genotypes in three geographically distant areas of Spain, 2011–2012

Case Report

Staphylococcus aureus infection of the feet following fish pedicure

Clinical and Epidemiological Study

Antibiotic de-escalation in bacteremic urinary tract infections: potential opportunities and effect on outcome

Images in Infection

Not only fever and palmoplantar vesicular eruption

Correspondence

Clostridium difficile 027 increasing detection in a teaching hospital in Rome, Italy

Clinical and Epidemiological Study

Clinical course and quality of care in ART-naïve patients newly presenting in a HIV outpatient clinic
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits